Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Uchio, Edward
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
ENLIGHTED, NCT04620239 / 2020-004494-41: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study	Recruiting	3	100	Europe, US, RoW	padeliporfin VTP, WST11	Steba Biotech S.A., PrimeVigilance, ICON plc	Transitional Cell Cancer of Renal Pelvis and Ureter	12/24	01/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve	Recruiting	1/2	222	Canada, US	EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2	enGene, Inc.	Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	06/25	05/27
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue	Active, not recruiting	N/A	121	US	Irreversible Electroporation, The NanoKnife System	Angiodynamics, Inc.	Prostate Cancer	07/24	07/24